Daptomycin (Daptomycin) Patent Expiration, LOE Window & CMS Spending
Daptomycin (Daptomycin) by Sagent: FDA Orange Book LOE 2043-01-09, 23 AB generics, $152.4M 2024 CMS Part D & Medicaid spend, and $4,450 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sagent |
| FDA Application & Pathway | N208385 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2043-01-09 |
| Orange Book Patents (*PED Extensions) | 5 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 23 |
| 2024 CMS Total Public Spend | $152.4M |
| 2024 Medicare Part D Spend | $120.7M |
| 2024 Medicaid Spend | $31.8M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($4,450 intro WAC) |